How long should Eliquis (apixaban) be stopped before an endoscopy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

How Long to Stop Eliquis Before Endoscopy

For high-risk endoscopic procedures (polypectomy, EMR, ESD, sphincterotomy), stop Eliquis 3 days (72 hours) before the procedure if renal function is normal. 1

Risk Stratification of Endoscopic Procedures

The first critical step is determining whether your endoscopy is low-risk or high-risk for bleeding:

Low-Risk Procedures

  • Diagnostic endoscopy with or without biopsies 1
  • Biliary or pancreatic stenting without sphincterotomy 1
  • EUS without sampling or interventional therapy 1

High-Risk Procedures

  • Polypectomy 1
  • ERCP with sphincterotomy 1
  • EMR (endoscopic mucosal resection) or ESD (endoscopic submucosal dissection) 1
  • Endoscopic dilation of strictures 1
  • PEG (percutaneous endoscopic gastrostomy) placement 1
  • EUS with fine needle aspiration or interventional therapy 1
  • Treatment of varices 1

Discontinuation Protocol

For Low-Risk Procedures

Simply omit the morning dose of Eliquis on the day of the procedure. 1, 2, 3 No extended discontinuation period is needed, and bridging anticoagulation is not required. 1

For High-Risk Procedures with Normal Renal Function

Stop Eliquis 3 days (72 hours) before the procedure. 1, 2 This updated recommendation from the 2021 BSG/ESGE guidelines supersedes the older 48-hour recommendation from 2016. 1

For High-Risk Procedures with Impaired Renal Function

If creatinine clearance (CrCl) or eGFR is 30-50 mL/min, stop Eliquis 5 days (120 hours) before the procedure. 1, 2 This extended period accounts for reduced drug clearance in renal impairment.

For Rapidly Deteriorating Renal Function

Consult a hematologist immediately to determine the appropriate discontinuation timing and assess whether additional interventions are needed. 1

FDA-Approved Guidance

The FDA label for apixaban states: "Apixaban tablets should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable or clinically significant bleeding." 4 However, the more recent 2021 guideline recommendation of 3 days for high-risk endoscopic procedures represents current best practice based on accumulated clinical experience. 1

Resumption Protocol

Resume Eliquis 24-72 hours after the procedure once adequate hemostasis has been achieved. 1, 2 The specific timing within this window depends on:

  • Bleeding risk of the procedure performed - higher risk procedures warrant waiting closer to 72 hours 1
  • Adequacy of hemostasis achieved - if hemostasis is uncertain, delay resumption 1
  • Thrombotic risk of the patient - higher thrombotic risk may favor earlier resumption (closer to 24 hours) 1

The FDA label confirms: "Apixaban tablets should be restarted after the surgical or other procedures as soon as adequate hemostasis has been established." 4

Critical Pitfalls to Avoid

Do not account only for the 48-hour recommendation from older guidelines or the FDA label - the 2021 BSG/ESGE guideline specifically updated this to 3 days for high-risk procedures based on accumulated evidence. 1

Do not fail to assess renal function before determining discontinuation timing - patients with CrCl 30-50 mL/min require 5 days off Eliquis, not 3 days. 1, 2 Failure to extend the discontinuation period in renal impairment increases bleeding risk significantly.

Do not resume Eliquis too early after polypectomy or other high-risk interventions - premature resumption (before 24 hours) substantially increases post-procedure bleeding risk. 2

Bridging anticoagulation is NOT recommended when discontinuing Eliquis for endoscopy, even in high thrombotic risk patients. 1, 4 The short half-life of DOACs makes bridging unnecessary and potentially harmful.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Apixaban Before Colonoscopy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Apixaban Before EGD

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.